Literature DB >> 2153310

Gliomas: classification with MR imaging.

B L Dean1, B P Drayer, C R Bird, R A Flom, J A Hodak, S W Coons, R G Carey.   

Abstract

The findings at magnetic resonance (MR) imaging in a group of 36 pathologically verified supratentorial gliomas were analyzed and compared with the biopsy diagnoses (a) to determine whether MR imaging could be used to classify astrocytic-series tumors into a three-tiered system of low-grade astrocytoma, anaplastic astrocytoma, and glioblastoma multiforme; and (b) to evaluate MR imaging features that may aid in this classification. The MR characteristics evaluated were crossing of the midline, edema, tumor signal heterogeneity, hemorrhage, border definition, cyst formation or necrosis, and mass effect. The statistically significant MR characteristics (positive predictors) were mass effect (P = .0000) and cyst formation or necrosis (P = .0512). The MR accuracy rate approached that of neuropathologic diagnosis, which is subject to sampling errors. MR imaging may serve as an adjunct in case management when the clinical course and MR findings appear to be at odds with the neuropathologic diagnosis.

Entities:  

Mesh:

Year:  1990        PMID: 2153310     DOI: 10.1148/radiology.174.2.2153310

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  68 in total

1.  MR imaging characteristics of protoplasmic astrocytomas.

Authors:  Kevin L Tay; Alpha Tsui; Pramit M Phal; Katharine J Drummond; Brian M Tress
Journal:  Neuroradiology       Date:  2010-07-20       Impact factor: 2.804

2.  Improved Differentiation of Low-Grade and High-Grade Gliomas and Detection of Tumor Proliferation Using APT Contrast Fitted from Z-Spectrum.

Authors:  Jiaxuan Zhang; Wenzhen Zhu; Rongwen Tain; Xiaohong Joe Zhou; Kejia Cai
Journal:  Mol Imaging Biol       Date:  2018-08       Impact factor: 3.488

Review 3.  Intra-axial brain tumours.

Authors:  G Wilms; Ph Demaerel; S Sunaert
Journal:  Eur Radiol       Date:  2004-12-31       Impact factor: 5.315

Review 4.  Management of newly diagnosed glioblastoma: guidelines development, value and application.

Authors:  Jeffrey J Olson; Camilo E Fadul; Daniel J Brat; Srinivasan Mukundan; Timothy C Ryken
Journal:  J Neurooncol       Date:  2009-05-09       Impact factor: 4.130

5.  Postmortem MRI of the brain with neuropathological correlation.

Authors:  L van den Hauwe; P M Parizel; J J Martin; P Cras; P De Deyn; A M De Schepper
Journal:  Neuroradiology       Date:  1995-07       Impact factor: 2.804

6.  High- and low-grade glioma differentiation: the role of percentage signal recovery evaluation in MR dynamic susceptibility contrast imaging.

Authors:  Italo Aprile; Giorgia Giovannelli; Paola Fiaschini; Marco Muti; Anna Kouleridou; Nevia Caputo
Journal:  Radiol Med       Date:  2015-03-12       Impact factor: 3.469

7.  Multimodal MR imaging (diffusion, perfusion, and spectroscopy): is it possible to distinguish oligodendroglial tumor grade and 1p/19q codeletion in the pretherapeutic diagnosis?

Authors:  S Fellah; D Caudal; A M De Paula; P Dory-Lautrec; D Figarella-Branger; O Chinot; P Metellus; P J Cozzone; S Confort-Gouny; B Ghattas; V Callot; N Girard
Journal:  AJNR Am J Neuroradiol       Date:  2012-12-06       Impact factor: 3.825

8.  Measurements of heterogeneity in gliomas on computed tomography relationship to tumour grade.

Authors:  Karoline Skogen; Balaji Ganeshan; Catriona Good; Giles Critchley; Ken Miles
Journal:  J Neurooncol       Date:  2012-12-06       Impact factor: 4.130

9.  Multiparametric characterization of grade 2 glioma subtypes using magnetic resonance spectroscopic, perfusion, and diffusion imaging.

Authors:  Wei Bian; Inas S Khayal; Janine M Lupo; Colleen McGue; Scott Vandenberg; Kathleen R Lamborn; Susan M Chang; Soonmee Cha; Sarah J Nelson
Journal:  Transl Oncol       Date:  2009-12       Impact factor: 4.243

10.  Proton MR spectroscopy of tumefactive demyelinating lesions.

Authors:  Amit M Saindane; Soonmee Cha; Meng Law; Xiaonan Xue; Edmond A Knopp; David Zagzag
Journal:  AJNR Am J Neuroradiol       Date:  2002-09       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.